Journals / Medicine Science / 2020 / Cilt: 9 - Sayı: 2

The effect of orlistat treatment on cardiovascular novel inflammatory biomarkers

Pages
427–432
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our study, we observed that inflammatory markers such as hs-CRP and MHR and CRR improved significantly as a result of decreased weight with orlistat treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Increase in prevalence of obesity has become a worldwide major health problem.
📊
Key Findings & Data:In general, greater body mass index (BMI) is associated with increased rate of death.
💡
Conclusion & Impact:In our study, we observed that inflammatory markers such as hs-CRP and MHR and CRR improved significantly as a result of decreased weight with orlistat treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Increase in prevalence of obesity has become a worldwide major health problem. In general, greater body mass index (BMI) is associated with increased rate of death. New inflammatory markers (such as monocyte-to-HDL ratio (MHR), and cardiac risk ratio (CRR)) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine. Although they have been tested in many different diseases and conditions, how they have been affected in patients receiving orlistat therapy due to obesity has never been evaluated before. In this retrospective study, 197 patients who received orlistat treatment for the first time were included in the study were enrolled. All data (such as demographic profile, lipid profile, hs-CRP, hemogram, and biochemical parameters) of patients before the treatment and at the 3rd-month control after orlistat treatment were recorded. The gender ratios of the patients were male (%46.7) and female (%53.3) and mean age of patients was 47.13±10.9 years. In the comparison of patients before and after treatment, BMI was significantly decreased and the mean change was 3.4054 (p<0.001). Significant decrease in neutrophil (5.71±1.9, 5.39±1.5, p=0.016), monocyte (0.572±0.207, 0.508±0.164, p<0.001), and platelets (309.09±102.1, 276.08±60.2, p=0.023) were observed in blood cells. When the inflammatory parameters were examined, a significant decrease in hs-CRP (0.88±0.52, 0.67±0.28, p<0.001), in CRR (4.32±1.07, 3.94±0.92, p<0.001), in MHR (0.0135±0.0057, 0.0116±0.0049, p<0.001) were observed (before and after orlistat treatment, respectively). Also, significant improvement was observed in the lipid profile of the patients after orlistat treatment (for all values, p<0.05). In our study, we observed that inflammatory markers such as hs-CRP and MHR and CRR improved significantly as a result of decreased weight with orlistat treatment.

🔖

Cite This Article

YALİM, Z., YALİM, S. A. (2020). The effect of orlistat treatment on cardiovascular novel inflammatory biomarkers. Medicine Science, Cilt: 9 - Sayı: 2, 427–432. https://ajindex.com/articles/270454

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1–17
  2. Obesity and overweight [Internet]. 16 February 2018. Available from: https:// www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight 3. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA. 2006;296:79–86
  3. Afshin A, Forouzanfar MH, Reitsma MB, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13–27
  4. Saunders KH, Umashanker D, Igel LI, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018;102:135–48
  5. Bolayir A, Bolayir E. Can lymphocyte to monocyte ratio be used as a predictor of atherosclerotic carotid plaques in elderly adults? Cumhur Tıp Derg. 2017;40:120–7
  6. Cetin EHO, Cetin MS, Canpolat U, et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark Med. 2015;9:967–77
  7. Dobiasova M. AIP, Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52:64–71
  8. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102:653–7
  9. E. Turan, “Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves’ disease.,” Bratisl. Lek. Listy, vol. 120, no. 6, pp. 476–80, 2019
  10. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):102-38
  11. Bray GA, Fruhbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet (London, England). 2016;387:1947–56
  12. Vallis M. Quality of life and psychological well-being in obesity management: improving the odds of success by managing distress. Int J Clin Pract. 2016;70:196–205
  13. Wilding J. Orlistat: should we worry about liver inflammation? Vol. 346, BMJ (Clinical research ed.). England; 2013. p. f2777
  14. Yesilbursa D, Serdar A, Heper Y, et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol. 2005;60:265–9
  15. Hsieh C-J, Wang P-W,